#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic kidney disease Rheumatoid arthritis Pericarditis Glomerulonephritis acute Chronic graft versus host disease in liver Mitochondrial encephalomyopathy B-cell small lymphocytic lymphoma recurrent Juvenile chronic myelomonocytic leukaemia B-cell lymphoma recurrent Pouchitis Loss of consciousness Ovarian cancer stage IV Malformation venous Nasopharyngeal cancer Macular telangiectasia More trials…

    Learn about Rare Diseases

    Mucous membrane pemphigoid – Treatment Osteosarcoma recurrent – Life with Disease Lysosomal storage disorder – Diagnostics Haemophilia A without inhibitors – Life with Disease Retinoblastoma – Basic Information Alport’s syndrome – Diagnostics Rett syndrome – Trials in Disease Acute respiratory distress syndrome – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Netherton’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fipaxalparant Olopatadine Baricitinib VALACICLOVIR HYDROCHLORIDE Avibactam Quinidine Sulfate BIIB115 Senicapoc Zenocutuzumab Soticlestat Xxb750 Amantadine Hemisulfate Glycerol Phenylbutyrate CITRIC ACID ANHYDROUS Betaxolol Vincristine Sulfate Pentosan Polysulfate Sodium ALG-000184 Kd050 Cefazolin More therapies…

    Learn about Your Condition

    Dementia Alzheimer's type Kidney transplant rejection Infection Vertigo Tendon injury Paresis Cardiac valve disease Impaired gastric emptying Spinal cord injury cervical Lymphocytic lymphoma Turner's syndrome Primary hyperoxaluria Bile duct adenocarcinoma Hyperphagia Sciatica More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 negative breast cancer

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

    Not recruiting

    2 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Metastases to central nervous system
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Austria Spain

  • Study on Olaparib for Patients with Advanced HER2-Negative Breast Cancer and Specific Genetic Mutations

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    Investigated Drugs:
    • Olaparib
    Spain

  • Study of Milademetan and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer with GATA3 Mutation, ER-Positive, HER2-Negative

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    Investigated Drugs:
    • Milademetan
    • Fulvestrant
    France

  • Study on Irinotecan for Brain Metastases in Patients with HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    Investigated Drugs:
    • Irinotecan
    Spain

  • Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 negative breast cancer
    • Hormone receptor negative HER2 positive breast cancer
    • Oestrogen receptor gene overexpression
    Investigated Drugs:
    • Fluoroestradiol F-18
    France
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!